Allogene Therapeutics Financials
Allogene Therapeutics (ALLO) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Allogene’s development-stage model is funded by external capital while operating spending, not fixed assets, drives cash consumption.
From FY2023 to FY2024, both R&D and operating cash outflow declined, but FCF remained nearly identical to operating cash flow. With FY2024 capex at$694K , the cash-conversion pattern shows that funding needs are overwhelmingly tied to the research program rather than heavy physical reinvestment.
FY2024 reported revenue was
FY2024 liabilities of
Financial Health Signals
Allogene Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Allogene Therapeutics scores -4.38, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($697.9M) relative to total liabilities ($123.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Allogene Therapeutics passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Allogene Therapeutics reported a net loss of $190.9M while operations used $149.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Allogene Therapeutics reported an operating loss of $209.3M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Allogene Therapeutics generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Allogene Therapeutics's EBITDA was -$197.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.1% from the prior year.
Allogene Therapeutics reported -$190.9M in net income in fiscal year 2025. This represents an increase of 25.9% from the prior year.
Allogene Therapeutics earned -$0.87 per diluted share (EPS) in fiscal year 2025. This represents an increase of 34.1% from the prior year.
Cash & Balance Sheet
Allogene Therapeutics recorded an outflow of $149.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 25.6% from the prior year.
Allogene Therapeutics held $51.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Allogene Therapeutics paid $0.00 per share in dividends in fiscal year 2025.
Margins & Returns
Allogene Therapeutics's ROE was -65.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Allogene Therapeutics invested $150.2M in research and development in fiscal year 2025. This represents a decrease of 21.9% from the prior year.
Allogene Therapeutics invested $386K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 44.4% from the prior year.
Not reported for fiscal year 2025.
ALLO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | N/A | N/A | $0 | $0 | $0 | N/A | $0 |
| R&D Expenses | $30.7M-4.0% | $32.0M | N/A | $31.2M-22.4% | $40.2M-20.0% | $50.2M | N/A | $44.7M |
| SG&A Expenses | $20.8M+47.9% | $14.1M | N/A | $13.7M-3.8% | $14.3M-4.7% | $15.0M | N/A | $16.3M |
| Operating Income | -$46.9M-1.8% | -$46.1M | N/A | -$44.9M+21.0% | -$56.8M+12.8% | -$65.2M | N/A | -$71.8M |
| Interest Expense | $343K+14.3% | $300K | N/A | $344K+28.4% | $268K+78.7% | $150K | N/A | $100K |
| Net Income | -$42.7M-0.2% | -$42.6M | N/A | -$41.4M+18.7% | -$50.9M+14.7% | -$59.7M | N/A | -$66.3M |
| EPS (Diluted) | -$0.13+27.8% | -$0.18-5.9% | -$0.17+10.5% | -$0.19+17.4% | -$0.23+17.9% | -$0.280.0% | -$0.28+12.5% | -$0.32 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
ALLO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $550.1M+38.9% | $396.0M-4.8% | $415.9M-5.4% | $439.8M-6.5% | $470.6M-7.4% | $508.0M-7.4% | $548.7M-6.9% | $589.1M |
| Current Assets | $340.0M+24.4% | $273.3M+6.0% | $257.7M-1.1% | $260.7M-7.8% | $282.7M-3.1% | $291.6M-3.9% | $303.4M-0.3% | $304.4M |
| Cash & Equivalents | $38.6M+27.4% | $30.3M-41.4% | $51.7M+36.7% | $37.8M-27.7% | $52.3M+23.3% | $42.5M-43.6% | $75.2M+46.8% | $51.2M |
| Total Liabilities | $113.9M-2.7% | $117.1M-5.1% | $123.4M-0.9% | $124.4M-1.3% | $126.0M+2.8% | $122.6M-3.1% | $126.5M+0.9% | $125.4M |
| Current Liabilities | $31.7M+12.0% | $28.3M-12.9% | $32.5M+2.1% | $31.8M+0.5% | $31.7M+5.5% | $30.0M-15.5% | $35.5M+9.1% | $32.6M |
| Total Equity | $436.2M+56.4% | $278.9M-4.7% | $292.5M-7.2% | $315.3M-8.5% | $344.6M-10.6% | $385.4M-8.7% | $422.2M-9.0% | $463.7M |
| Retained Earnings | -$2.1B-2.1% | -$2.1B-2.1% | -$2.0B-2.0% | -$2.0B-2.1% | -$1.9B-2.7% | -$1.9B-3.3% | -$1.8B-3.4% | -$1.8B |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ALLO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.0M-147.8% | -$12.9M+53.2% | -$27.6M+7.0% | -$29.7M+23.9% | -$39.0M+26.3% | -$52.9M-44.2% | -$36.7M+16.8% | -$44.1M |
| Capital Expenditures | $150K+1566.7% | $9K | $0-100.0% | $243K+452.3% | $44K-55.6% | $99K-61.5% | $257K-40.1% | $429K |
| Free Cash Flow | -$32.1M-148.8% | -$12.9M+53.2% | -$27.6M+7.8% | -$29.9M+23.4% | -$39.1M+26.3% | -$53.0M-43.5% | -$37.0M+17.0% | -$44.5M |
| Investing Cash Flow | -$147.6M-398.7% | -$29.6M-188.0% | $33.6M+181.6% | $11.9M-72.8% | $43.8M+609.8% | $6.2M-88.8% | $54.9M+172.3% | -$76.0M |
| Financing Cash Flow | $187.9M+789.5% | $21.1M+168.8% | $7.9M+142.9% | $3.2M-36.2% | $5.1M-63.7% | $14.0M+143.6% | $5.7M+745.8% | $679K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ALLO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1011.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -919.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -9.8%+5.5pp | -15.3% | N/A | -13.1%+1.6pp | -14.8%+0.7pp | -15.5% | N/A | -14.3% |
| Return on Assets | -7.8%+3.0pp | -10.8% | N/A | -9.4%+1.4pp | -10.8%+0.9pp | -11.8% | N/A | -11.3% |
| Current Ratio | 10.72+1.1x | 9.65+1.7x | 7.93-0.3x | 8.19-0.7x | 8.92-0.8x | 9.71+1.2x | 8.54-0.8x | 9.35 |
| Debt-to-Equity | 0.26-0.2x | 0.420.0x | 0.420.0x | 0.390.0x | 0.370.0x | 0.320.0x | 0.300.0x | 0.27 |
| FCF Margin | -692.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Allogene Therapeutics Ranks
Frequently Asked Questions
What is Allogene Therapeutics's annual revenue?
Allogene Therapeutics (ALLO) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Allogene Therapeutics's revenue growing?
Allogene Therapeutics (ALLO) revenue declined by 100.0% year-over-year, from $22K to $0 in fiscal year 2025.
Is Allogene Therapeutics profitable?
No, Allogene Therapeutics (ALLO) reported a net income of -$190.9M in fiscal year 2025.
What is Allogene Therapeutics's EBITDA?
Allogene Therapeutics (ALLO) had EBITDA of -$197.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Allogene Therapeutics's return on equity (ROE)?
Allogene Therapeutics (ALLO) has a return on equity of -65.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Allogene Therapeutics's free cash flow?
Allogene Therapeutics (ALLO) recorded an outflow of $149.6M in free cash flow during fiscal year 2025. This represents a 25.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Allogene Therapeutics's operating cash flow?
Allogene Therapeutics (ALLO) recorded an outflow of $149.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Allogene Therapeutics's total assets?
Allogene Therapeutics (ALLO) had $415.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Allogene Therapeutics's capital expenditures?
Allogene Therapeutics (ALLO) invested $386K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Allogene Therapeutics spend on research and development?
Allogene Therapeutics (ALLO) invested $150.2M in research and development during fiscal year 2025.
What is Allogene Therapeutics's current ratio?
Allogene Therapeutics (ALLO) had a current ratio of 7.93 as of fiscal year 2025, which is generally considered healthy.
What is Allogene Therapeutics's debt-to-equity ratio?
Allogene Therapeutics (ALLO) had a debt-to-equity ratio of 0.42 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Allogene Therapeutics's return on assets (ROA)?
Allogene Therapeutics (ALLO) had a return on assets of -45.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Allogene Therapeutics's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Allogene Therapeutics (ALLO) held $258.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $149.2M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Allogene Therapeutics's Altman Z-Score?
Allogene Therapeutics (ALLO) has an Altman Z-Score of -4.38, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Allogene Therapeutics's Piotroski F-Score?
Allogene Therapeutics (ALLO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Allogene Therapeutics's earnings high quality?
Allogene Therapeutics (ALLO) reported a net loss of $190.9M while operations used $149.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Allogene Therapeutics cover its interest payments?
Allogene Therapeutics (ALLO) reported an operating loss of $209.3M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.